Citation Report
List of articles citing

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs

DOI: 10.2165/00003088-200544030-00005
Clinical Pharmacokinetics, 2005, 44, 279-304.

#	Paper	IF	Citations
378	High throughput P450 inhibition screens in early drug discovery. **2005**, 10, 1443-50		80
377	In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. **2005**, 20, 351-7		34
376	Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. **2005**, 33, 1637-47		93
375	Applications of AmpliChip CYP450. *Molecular Diagnosis and Therapy*, **2005**, 9, 119-127		10
374	Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model. **2006**, 36, 351-65		12
373	Drug Interactions of Medications Commonly Used in Diabetes. **2006**, 19, 202-211		36
372	Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. **2006**, 34, 166-75		146
371	Drug-associated disease: cytochrome P450 interactions. **2006**, 22, 329-45, vii		36
370	Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions. **2006**, 36, 1013-80		24
369	Organotypic cultures represent tumor microenvironment for drug testing. **2006**, 3, 143-148		6
368	Structure Activity Relationships for In vitro and In vivo Toxicity. **2006**, 41, 353-368		48
367	Clopidogrel-statin interaction: a mountain or a mole hill?. **2006**, 152, 200-3		17
366	Monitoring drug-protein interaction. **2006**, 365, 9-29		28
365	Solifenacin succinate for the treatment of symptoms of overactive bladder. **2006**, 28, 1247-72		40
364	Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats. **2006**, 79, 50-6		12
363	In vitro methods in human drug biotransformation research: implications for cancer chemotherapy. **2006**, 20, 135-53		30
362	Effects of highly active antiretroviral therapy and immune recovery on CD8+ T-cell-mediated inhibition of HIV-1 transcription. **2006**, 43, 393-400		

361	Prevalence and characteristics of adverse drug reactions in neurosurgical intensive care patients. **2006**, 58, 426-33; discussion 426-33		15
360	Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. **2006**, 155, 261-6		80
359	A clinical drug library screen identifies astemizole as an antimalarial agent. **2006**, 2, 415-6		231
358	Therapeutic potential of resveratrol: the in vivo evidence. **2006**, 5, 493-506		2806
357	A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients. **2006**, 837, 69-75		24
356	Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. *European Journal of Clinical Pharmacology*, **2006**, 62, 597-603	2.8	16
355	Statin safety: a systematic review. **2006**, 97, 52C-60C		556
354	Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. **2006**, 2, 981-1007		6
353	Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines. **2006**, 34, 2102-10		4
352	Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection. **2006**, 3, 385-390		
351	Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. **2006**, 34, 1291-300		94
350	Idiosyncratic toxicity: a convergence of risk factors. **2007**, 58, 17-34		96
349	Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. **2007**, 35, 1232-8		61
348	Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3185-9	5.9	34
347	Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. **2007**, 29, 687-710		265
346	Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. **2007**, 153, 891-9		305
345	Natural antioxidants in Alzheimer's disease. **2007**, 16, 1921-31		113
344	The Use of Dasatinib in Chronic Myeloid Leukemia: Some Practical Considerations. **2007**, 1, 229-233		7

343	Application of chimeric mice with humanized liver for predictive ADME. **2007**, 39, 145-57		45
342	Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. *Journal of Clinical Pharmacology*, **2007**, 47, 871-6	2.9	35
341	Incorporating Genome-Based Technologies into Toxicology and Safety Assessments for Drug Discovery and Development. **2007**, 21, 427-438		1
340	Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. **2007**, 55, 310-7		58
339	Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. *Journal of Clinical Pharmacology*, **2007**, 47, 165-74	2.9	54
338	Modeling and Simulation of Pharmacokinetic Aspects of Cytochrome P450-Based Metabolic DrugDrug Interactions. **2007**, 827-846		2
337	Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. *World Journal of Gastroenterology*, **2007**, 13, 5618-28	5.6	11
336	Induction of Cytochrome P450 CYP3A by St John's Wort in the Rat Liver and Intestine. **2007**, 2, 117863370700200		0
335	Pharmacokinetics and metabolism of diltiazem in rats: comparing single vs repeated subcutaneous injections in vivo. **2007**, 28, 403-7		4
334	An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 874-8	2.9	18
333	Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. **2007**, 19, 30-8		89
332	The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. **2007**, 6, 636-49		264
331	Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. *British Journal of Clinical Pharmacology*, **2007**, 64, 668-79	3.8	62
330	The pivotal role of hepatocytes in drug discovery. **2007**, 168, 2-15		127
329	Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. **2007**, 31, 232-41		27
328	Drugs as CYP3A probes, inducers, and inhibitors. **2007**, 39, 699-721		144
327	Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. **2007**, 37, 389-412		64
326	Time-dependent CYP inhibition. **2007**, 3, 51-66		97

325	Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. **2007**, 60, 741-50		47
324	The evolving role of drug metabolism in drug discovery and development. **2007**, 24, 842-58		54
323	Computational models to assign biopharmaceutics drug disposition classification from molecular structure. **2007**, 24, 2249-62		51
322	The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. **2007**, 15, 251-7		51
321	Diagnostik und Psychopharmakotherapie depressiver Erkrankungen bei Herz-Kreislauf-Patienten vor konsiliarpsychiatrischem Hintergrund. **2007**, 1, 193-197		2
320	Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. **2008**, 26, 119-37		4
319	Serotonin pharmacology in the gastrointestinal tract: a review. **2008**, 377, 181-203		77
318	Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. **2008**, 21, 189-205		141
317	In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. *AAPS Journal*, **2008**, 10, 410-24	3.7	127
316	Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. **2008**, 83, 153-9		28
315	Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. **2008**, 579, 104-9		43
314	General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. *Clinical Pharmacokinetics*, **2008**, 47, 669-80	6.2	73
313	Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. **2008**, 21, 129-37		171
312	Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. **2008**, 30, 1639-50		20
311	Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance. **2008** , 40, 101-47		45
310	Elvitegravir: an emerging HIV integrase inhibitor. **2008**, 2, 411-418		2
309	Inflammatory reactions and drug response: importance of cytochrome P450 and membrane transporters. **2008**, 1, 627-47		14
308	Xenobiotic Metabolism. **2008**, 1		

307	Tissue processing of nitrite in hypoxia: an intricate interplay of nitric oxide-generating and -scavenging systems. **2008**, 283, 33927-34		177
306	Medications for Extensively Drug-Resistant Tuberculosis: Back to the Future?. **2008**, 24, 82-95		
305	Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers. **2008**, 23, 428-33		1
304	The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo. **2008**, 4, 151-64		15
303	The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. **2008**, 36, 1291-9		25
302	Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. **2008**, 49, 156-62		21
301	Coronary artery stents: II. Perioperative considerations and management. **2008**, 107, 570-90		87
300	Irreversible Cytochrome P450 Inhibition: Common Substructures and Implications for Drug Development. **2008**, 267-276		
299	Atorvastatin and cardiovascular risk in the elderly--patient considerations. **2008**, 3, 299-314		12
298	Cytochrome P450: Structure, Function, and Application in Drug Discovery and Development. 55-107		
297	Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. *Journal of Clinical Pharmacology*, **2009**, 49, 398-406	2.9	35
296	Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. **2009**, 10, 261-8		39
295	Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 2892-901	5.9	15
294	Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. **2009**, 39, 749-56		8
293	Drug□Drug Interactions with an Emphasis on Drug Metabolism and Transport. **2009**, 303-325		3
292	Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods. **2009**, 36, 175-91		87
291	Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: focus on CYP3A4. **2009**, 35, 417-29		22
290	Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. *European Journal of Clinical Pharmacology*, **2009**, 65, 667-78	2.8	27

289	Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. **2009**, 85, 64-70		80
288	SPORCalc: A development of a database analysis that provides putative metabolic enzyme reactions for ligand-based drug design. **2009**, 33, 149-59		12
287	Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6307-12	2.9	44
286	Application of mechanism-based CYP inhibition for predicting drug-drug interactions. **2009**, 5, 579-605		25
285	The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. **2009**, 37, 1355-70		242
284	Curcumin in clinical practice: myth or reality?. **2009**, 30, 333-4		56
283	Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. **2009**, 41, 1441-55		32
282	Vitamin E increases biomarkers of estrogen stimulation when taken with tamoxifen. **2009**, 153, 143-7		12
281	Fighting cancer with red wine? Molecular mechanisms of resveratrol. **2009**, 49, 782-99		75
280	Approaches for the development of antiviral compounds: the case of hepatitis C virus. **2009**, 25-51		8
279	Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. **2009**, 22, 1298-309		65
278	Drug interactions. **2009**, 41, 486-527		41
277	Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. **2009**, 85, 644-50		23
276	Covalent modifiers: an orthogonal approach to drug design. *Journal of Medicinal Chemistry*, **2009**, 52, 1231-46	8.3	278
275	Drug Metabolism. **2009**, 131-173		13
274	Pathogenesis of bone disorders in HIV infection. **2009**, 4, 147-159		0
273	Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. **2009**, 51, 424-9		69
272	Propofol reduces the distribution and clearance of midazolam. **2010**, 110, 1597-606		29

271	Update information on drug metabolism systems--2009, part I. *Current Drug Metabolism*, **2010**, 11, 1-3	3.5	42
270	Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice. **2010**, 25, 93-100		19
269	Docosahexaenoic acid (DHA) inhibits saquinavir metabolism in-vitro and enhances its bioavailability in rats. **2006**, 58, 651-8		7
268	Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. *European Journal of Clinical Pharmacology*, **2010**, 66, 1131-6	2.8	40
267	Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition. **2010**, 24, 891-906		27
266	A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. **2010**, 100, 261-8		18
265	A pharmacodynamic-pharmacokinetic (PD-PK) study on the effects of Danshen (Salvia miltiorrhiza) on midazolam, a model CYP3A probe substrate, in the rat. **2010**, 17, 876-83		21
264	Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. **2010**, 99, 486-514		51
263	Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2344-9	2.9	6
262	2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3941-5	2.9	25
261	Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. **2010**, 87, 191-6		43
260	Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. **2010**, 334, 999-1008		37
259	Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1 (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro. **2010**, 38, 249-59		7
258	Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes. **2010**, 38, 1522-31		11
257	Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction. **2010**, 38, 841-50		13
256	Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. **2010**, 42, 268-354		186
255	Secondary Pharmacodynamic Studies and In vitro Pharmacological Profiling. **2010**, 1		
254	The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. **2010**, 6, 1215-30		10

253	Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. **2010**, 42, 380-401		81
252	Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. **2010**, 401, 149-53		42
251	[Mechanisms of pharmacokinetic drug-drug interactions]. **2010**, 31, 170-9		14
250	In Vitro Techniques to Study Drug□Drug Interactions of Drug Metabolism: Cytochrome P450. **2010**, 169-215		5
249	Effects of herbal products on the metabolism and transport of anticancer agents. **2010**, 6, 1195-213		39
248	Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?. *Journal of Clinical Pharmacology*, **2011**, 51, 1561-70	2.9	24
247	A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. **2011**, 63, 390-410		85
246	Cree antidiabetic plant extracts display mechanism-based inactivation of CYP3A4. **2011**, 89, 13-23		13
245	Pharmacogenomics and adverse drug reactions: the case of statins. **2011**, 12, 1499-509		18
244	Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. **2011**, 7, 609-22		14
243	3,4-methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition. **2011**, 203, 82-91		12
242	Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. **2011**, 3, 745-81		31
241	Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. **2011**, 3, 13-25		16
240	Drug-Metabolizing Enzymes, Transporters, and Drug□Drug Interactions. **2011**, 83-149		1
239	Scientific Opinion on the safety of □lavonoid□ □an extract derived from the roots or rootstock of Glycyrrhiza glabra L., as a Novel Food ingredient. **2011**, 9, 2287		4
238	Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. **2011**, 90, 666-73		68
237	Architecture of the drug-drug interaction network. **2011**, 36, 135-43		10
236	Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs. **2011**, 35, 2121-7		23

235	Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. **2011**, 129, 267-89		41
234	Drugs in porphyria: From observation to a modern algorithm-based system for the prediction of porphyrogenicity. **2011**, 132, 158-69		36
233	Inhibitory effect of tanshinones on rat CYP3A2 and CYP2C11 activity and its structure-activity relationship. *Fitoterapia*, **2011**, 82, 539-45	3.2	20
232	Identification of cytochrome P450 (CYP) isoforms involved in the metabolism of corynoline, and assessment of its herb-drug interactions. **2011**, 25, 256-63		27
231	Effects of Salvia miltiorrhiza extract on the liver CYP3A activity in humans and rats. **2011**, 25, 1653-9		19
230	The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1376-81	2.9	17
229	Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. **2011**, 26, 154-61		27
228	Comparing pharmacokinetics and metabolism of diltiazem in normotensive Sprague Dawley and Wistar Kyoto rats vs. spontaneously hypertensive rats in vivo. **2011**, 26, 119-25		1
227	Sex differences in drug disposition. **2011**, 2011, 187103		158
226	CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. **2011**, 39, 1039-46		69
225	Cytochrome P450-mediated cardiovascular drug interactions. **2011**, 7, 1065-82		21
224	Mechanism-based inhibition of human cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content. **2012**, 42, 1163-9		12
223	Systemic effects of inhaled corticosteroids. **2012**, 18, 85-9		32
222	Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards. **2012**, 27, 520-9		45
221	Binding processes determine the stereoselective intestinal and hepatic extraction of verapamil in vivo. **2012**, 9, 3034-45		5
220	hERG K(+) channels: structure, function, and clinical significance. **2012**, 92, 1393-478		426
219	Natural substances and Alzheimer's disease: from preclinical studies to evidence based medicine. **2012**, 1822, 616-24		58
218	Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts. *Journal of Ethnopharmacology*, **2012**, 143, 586-91	5	12

217	Translational Drug Discovery Research: Integration of Medicinal Chemistry, Computational Modeling, Pharmacology, ADME, and Toxicology. **2012**, 1		3
216	Drug interaction potential of resveratrol. **2012**, 44, 253-65		70
215	Effects of Phyllanthus amarus on the pharmacokinetics of midazolam and cytochrome P450 activities in rats. **2012**, 42, 641-8		5
214	Technical Challenges and Recent Advances of Implementing Comprehensive ADMET Tools in Drug Discovery. **2012**, 129-159		1
213	Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. **2012**, 42, 238-55		18
212	Aloe vera juice: IC and dual mechanistic inhibition of CYP3A4 and CYP2D6. **2012**, 26, 445-51		19
211	Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations. **2012**, 52, 1573-82		68
210	Pivotal role of water in terminating enzymatic function: a density functional theory study of the mechanism-based inactivation of cytochromes P450. **2012**, 116, 7787-94		16
209	Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?. **2012**, 25, 513-31		92
208	Chapter 17:The Rational Design of Triple Reuptake Inhibitors for the Treatment of Depression. *RSC Drug Discovery Series*, **2012**, 270-289	0.6	
207	Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme. *Molecules*, **2012**, 17, 3407-60	4.8	19
206	Managing drug-drug interactions with boceprevir and telaprevir. **2012**, 1, 36-40		4
205	Identification and characterization of reactive metabolites in natural products-driven drug discovery. **2012**, 75, 507-13		26
204	Simultaneous online SPE-LC-MS/MS quantification of six widely used synthetic progestins in human plasma. **2012**, 403, 961-72		28
203	Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. **2012**, 198, 49-56		26
202	Investigation of cytochrome P450 1A2 and 3A inhibitory properties of Danshen tincture. **2012**, 19, 348-54		14
201	Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450. **2012**, 97, 219-28		6
200	The role of diet on the clinical pharmacology of oral antineoplastic agents. *European Journal of Clinical Pharmacology*, **2012**, 68, 115-22	2.8	13

199	Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions. **2013**, 33, 100-8		54
198	Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide. **2013**, 92, 1711-2		4
197	Potential food-drug interactions in patients with rheumatoid arthritis. **2013**, 16, 122-8		1
196	Drug-vitamin D interactions: a systematic review of the literature. **2013**, 28, 194-208		65
195	Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. **2013**, 33, 727-36		65
194	Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir. *Journal of Medicinal Chemistry*, **2013**, 56, 3733-41	8.3	51
193	A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. **2013**, 6, 249-69		36
192	Cytochrome P450 Activation of Toxins and Hepatotoxicity. **2013**, 15-33		2
191	How is a metabolic intermediate formed in the mechanism-based inactivation of cytochrome P450 by using 1,1-dimethylhydrazine: hydrogen abstraction or nitrogen oxidation?. **2013**, 19, 7361-9		30
190	NADPH P450 oxidoreductase: structure, function, and pathology of diseases. **2013**, 138, 229-54		153
189	Tactics to Avoid Inhibition of Cytochrome P450s. **2013**, 107-158		2
188	Importance of H-abstraction in the final step of nitrosoalkane formation in the mechanism-based inactivation of cytochrome P450 by amine-containing drugs. *International Journal of Molecular Sciences*, **2013**, 14, 24692-705	6.3	19
187	Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. **2013**, 41, 1843-51		20
186	Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. **2013**, 59, 407-13		7
185	Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. **2013**, 18, 118-27		48
184	Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. **2013**, 22, 578-92		59
183	High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy. **2013**, 63, 602-8		15
182	Drugs as victims and perpetrators and the pharmacokinetic concept of maximum exposure. **2014**, 1-21		1

181	Applications of density functional theory to iron-containing molecules of bioinorganic interest. **2014**, 2, 14		16
180	Drug and xenobiotic biotransformation in the blood-brain barrier: a neglected issue. **2014**, 8, 335		28
179	Cytochromes p450 and skin cancer: role of local endocrine pathways. **2014**, 14, 77-96		70
178	Challenges of Drug Delivery. **2014**, 29-54		
177	Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. **2014**, 59, 446-53		13
176	Phenotype standardization for statin-induced myotoxicity. **2014**, 96, 470-6		130
175	Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib. *Journal of Clinical Pharmacology*, **2014**, 54, 1280-9	2.9	14
174	Mechanism-based inactivation of human cytochrome P450 3A4 by two piperazine-containing compounds. **2014**, 42, 2087-96		2
173	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. **2014**, 406, 2325-32		28
172	Structure-based ligand design to overcome CYP inhibition in drug discovery projects. **2014**, 19, 905-11		51
171	Exploring concepts of in vitro time-dependent CYP inhibition assays. **2014**, 10, 157-74		26
170	Representation, Fingerprinting, and Modelling of Chemical Reactions. **2014**, 317-374		
169	Statin myotoxicity: a review of genetic susceptibility factors. **2014**, 24, 4-15		84
168	The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. **2014**, 35, 3044-51		63
167	Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2. *Journal of Medicinal Chemistry*, **2014**, 57, 9512-21	8.3	69
166	Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. **2014**, 44, 792-803		4
165	Click chemistry mediated Eu-tagging: activity-based specific quantification and simultaneous activity evaluation of CYP3A4 using 153Eu species-unspecific isotope dilution inductively coupled plasma mass spectrometry. **2014**, 86, 3688-92		16
164	Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models. **2014**, 46, 475-93		24

163	Experimental Approaches to Analysis of Reactions of Cytochrome P450 Enzymes. **2014**, 199-220		5
162	Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. **2014**, 60, 872-84		52
161	Inhibitory effects of celastrol on rat liver cytochrome P450 1A2, 2C11, 2D6, 2E1 and 3A2 activity. *Fitoterapia*, **2014**, 92, 1-8	3.2	46
160	Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations. **2014**, 124, 180-91		24
159	Drug-drug interactions in pharmacologic management of gastroparesis. **2015**, 27, 1528-41		16
158	Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS. **2015**, 9, 5763-9		6
157	Human Cytochrome P450 Enzymes. **2015**, 523-785		60
156	A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation. **2015**, 45, 961-77		31
155	HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. **2015**, 372, 613-20		147
154	Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling. **2015**, 11, 557-72		16
153	eCounterscreening: using QSAR predictions to prioritize testing for off-target activities and setting the balance between benefit and risk. **2015**, 55, 231-8		12
152	Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate. **2015**, 40, 389-99		6
151	Inhibitory Mechanisms of Human CYPs by Three Alkaloids Isolated from Traditional Chinese Herbs. **2015**, 29, 825-34		18
150	Effect of Chirality on Common in Vitro Experiments: An Enantiomeric Pair Analysis. *Journal of Medicinal Chemistry*, **2015**, 58, 5781-8	8.3	11
149	Benzyne Formation in the Mechanism-Based Inactivation of Cytochrome P450 by 1-Aminobenzotriazole and N-Benzyl-1-Aminobenzotriazole: Computational Insights. **2015**, 5, 2952-2960		11
148	The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity. **2015**, 25, 382-7		32
147	HIV-positive-to-HIV-positive kidney transplantation. **2015**, 372, 2070-1		11
146	Investigation of cytochrome P450 inhibitory properties of maslinic acid, a bioactive compound from Olea europaea L., and its structure-activity relationship. **2015**, 22, 56-65		17

145	SAR156497, an exquisitely selective inhibitor of aurora kinases. *Journal of Medicinal Chemistry*, **2015**, 58, 362-75	8.3	27
144	Time-dependent inhibition of CYP3A4 by gallic acid in human liver microsomes and recombinant systems. **2015**, 45, 213-7		7
143	Reversal of P-glycoprotein-medicated multidrug resistance by LBM-A5 in vitro and a study of its pharmacokinetics in vivo. **2015**, 93, 33-8		5
142	Development and validation of liquid chromatography tandem mass spectrometry method for simultaneous quantification of first line tuberculosis drugs and metabolites in human plasma and its application in clinical study. **2015**, 102, 253-60		26
141	Sex and Gender; Pharmacology, Efficacy, Toxicity, and Toxicology. 63-76		0
140	Differential Effects of Sunitinib on the Expression Profiles of Xenobiotic-Metabolizing Enzymes and Transporters in Rat Liver and Kidneys. **2016**, 119, 173-83		4
139	A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?. **2016**, 2, 187-192		13
138	Antitubulin Agents: Colchicine, Vinca Alkaloids, and Podophyllin. **2016**, 1-23		
137	Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate. **2016**, 163, 121-8		7
136	Gliptins in managing diabetes - Reviewing computational strategy. **2016**, 166, 108-120		22
135	Age-dependent features of CYP3A, CYP2C, and CYP2E1 functioning at metabolic syndrome. **2016**, 27, 603-610		3
134	Metabolism-Based Drug□Drug Interactions in Critically Ill Patients: Clinical Relevance and Predictability of In Vitro Systems. **2016**, 1-48		
133	Formation and inhibition of ethyl glucuronide and ethyl sulfate. **2016**, 265, 61-4		5
132	Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyri (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity. *Journal of Medicinal Chemistry*, **2016**, 59, 2328-42	8.3	25
131	Inhibition of CYP3A4 and CYP1A2 by Aegle marmelos and its constituents. **2016**, 46, 117-25		14
130	Identification of stable and reactive metabolite(s) of nelfinavir in human liver microsomes and rCYP3A4. **2016**, 118, 214-227		3
129	Identification and characterization of sulfonyltransferases catalyzing ethyl sulfate formation and their inhibition by polyphenols. **2016**, 130, 139-46		6
128	Effects of phillyrin and forsythoside A on rat cytochrome P450 activities in vivo and in vitro. **2017**, 47, 297-303		15

127	Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. **2017**, 110, 51-61	93
126	Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery. **2017**, 57, 616-626	8
125	Functional Coupling of Human Microphysiology Systems: Intestine, Liver, Kidney Proximal Tubule, Blood-Brain Barrier and Skeletal Muscle. **2017**, 7, 42296	157
124	Organochlorine pesticides and polychlorinated biphenyls in human adipose tissue from northern Tunisia: Current extent of contamination and contributions of socio-demographic characteristics and dietary habits. **2017**, 156, 635-643	15
123	Molecular docking simulations and GRID-independent molecular descriptor (GRIND) analysis to probe stereoselective interactions of CYP3A4 inhibitors. *Medicinal Chemistry Research*, **2017**, 26, 2322-2335	6
122	Rapid screening the potential mechanism-based inhibitors of CYP3A4 from Tripterygium wilfordi based on computer approaches combined with in vitro bioassay. **2017**, 25, 2689-2700	10
121	Dermatological Indications of Antihistamines. **2017**, 473-487	
120	Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention. **2017**, 5, e00294	45
119	Prolongation of the QTc interval in HIV-infected individuals compared to the general population. **2017**, 45, 659-667	13
118	Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. **2017**, 27, 329-336	37
117	Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model. **2017**, 25, 16	3
116	Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver. **2017**, 47, 488-497	4
115	Drug Metabolism in the Liver. **2017**, 21, 1-20	220
114	Appendix: Suggested Reading. **2017**, 699-741	
113	Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction. **2017**, 40, 2024-2037	1
112	Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel. **2017**, 12, 5537-5556	12
111	Discovery of AMG 337: Using Structure Guided Scaffold Hybridization to Optimize Physicochemical Properties and Target Coverage of a MET Kinase Inhibitor. **2017**, 138-160	
110	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. **2018**, 36, 624-632	36

109	Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. *European Journal of Clinical Pharmacology*, **2018**, 74, 755-765	2.8	19
108	Human and mouse artificial chromosome technologies for studies of pharmacokinetics and toxicokinetics. **2018**, 33, 17-30		15
107	Inhibition of CYP3A by Antimalarial Piperaquine and Its Metabolites in Human Liver Microsomes With IVIV Extrapolation. **2018**, 107, 1461-1467		3
106	Identification and analysis of the reactive metabolites related to the hepatotoxicity of safrole. **2018**, 48, 1164-1172		18
105	Precision medicine for HIV: where are we?. **2018**, 19, 145-165		9
104	An Integrated Population Pharmacokinetic Analysis to Characterize Levonorgestrel Pharmacokinetics After Different Administration Routes. *Journal of Clinical Pharmacology*, **2018**, 58, 1639-1654	2.9	15
103	Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study. **2018**, 26, 4984-4995		9
102	The metabolism distribution and effect of dinotefuran in Chinese lizards (Eremias argus). **2018**, 211, 591-599		7
101	The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies. *Therapeutics and Clinical Risk Management*, **2019**, 15, 921-936	2.9	9
100	Assessing Drug Interaction and Pharmacokinetics of Loxoprofen in Mice Treated with CYP3A Modulators. **2019**, 11,		0
99	Structural Insights into the Interaction of Cytochrome P450 3A4 with Suicide Substrates: Mibefradil, Azamulin and 6′,7′-Dihydroxybergamottin. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	6
98	Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. **2019**, 74, 21-28		16
97	Inhibitory kinetics of fruit components on CYP2C19 activity. **2019**, 34, 181-186		6
96	Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment. **2019**, 11, 39-50		4
95	Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. **2019**, 3, 908-916		25
94	Time-dependent inhibition of carbamazepine metabolism by piperine in anti-epileptic treatment. **2019**, 218, 314-323		8
93	Development and validation of a sensitive and specific LC-MS/MS cocktail assay for CYP450 enzymes: Application to study the effect of catechin on rat hepatic CYP activity. **2020**, 34, e4789		3
92	Recent advances in preclinical in‐vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters. **2020**, 35, 56-70		8

91	Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. **2020**, 206, 107449		13
90	Review - Treatment of Helicobacter pylori infection 2020. **2020**, 25 Suppl 1, e12743		8
89	Mechanistic studies on the drug metabolism and toxicity originating from cytochromes P450. **2020**, 52, 366-394		7
88	Side effects of a mixture of essential oils on Psyttalia concolor. **2020**, 29, 1358-1367		3
87	Pharmaceutical Excipients and Drug Metabolism: A Mini-Review. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
86	Role of Citrus Limonoid as a Possible Bioavailability Enhancer. **2020**, 859, 132-138		0
85	Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions. **2020**, 52, 235-257		14
84	Prediction of seriniquinone-drug interactions by in vitro inhibition of human cytochrome P450 enzymes. **2020**, 65, 104820		2
83	The Dual Role of ABC Transporters in Drug Metabolism and Resistance to Chemotherapy. **2020**, 1007-1014		0
82	Transchromosomic technology for genomically humanized animals. **2020**, 390, 111914		10
81	Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. **2020**, 8,		20
80	Assessment of inhibitory effects of novel anti MRSA benzoquinolizine fluoroquinolone WCK 771 (levonadifloxacin) and its metabolite on human liver cytochrome P450 enzymes. **2020**, 50, 1149-1157		3
79	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. **2021**, 893, 173813		14
78	Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein. *Journal of Clinical Pharmacology*, **2021**, 61, 298-306	2.9	0
77	Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms. *European Journal of Clinical Pharmacology*, **2021**, 77, 71-77	2.8	2
76	Innovation in bioanalytical strategies and drug-drug interaction study approaches in drug discovery. *Bioanalysis*, **2021**, 13, 513-532	2.1	3
75	Drug-Metabolizing Cytochrome P450 Enzymes Have Multifarious Influences on Treatment Outcomes. *Clinical Pharmacokinetics*, **2021**, 60, 585-601	6.2	9
74	Creation of a new class of radiosensitizers for glioblastoma based on the mibefradil pharmacophore. *Oncotarget*, **2021**, 12, 891-906	3.3	1

73	Acute Angle-Closure A Rare but Vision-Threatening Ocular Adverse Effect of Selective Serotonin Reuptake Inhibitors. *Applied Sciences (Switzerland)*, **2021**, 11, 3140	2.6	
72	Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations. *British Journal of Clinical Pharmacology*, **2021**, 87, 3244-3254	3.8	3
71	Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined Pharmacokinetic and Pharmacodynamic Modeling Approach. *ACS Chemical Neuroscience*, **2021**, 12, 1777-1790	5.7	2
70	The Tannins from L. (Rosaceae): A Systematic Study on the Metabolites of Rats Based on HPLC-LTQ-Orbitrap MS Analysis. *Molecules*, **2021**, 26,	4.8	1
69	The inhibitory effect of 225 frequently-used traditional Chinese medicines for CYP3A4 metabolic enzyme by isoform-specific probe. *F oterap* **2021**, 152, 104858	3.2	0
68	Current trends on resveratrol bioactivities to treat periodontitis. *Food Bioscience*, **2021**, 42, 101205	4.9	2
67	The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
66	Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin. *AAPS Journal*, **2021**, 23, 104	3.7	4
65	Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants: Comparison with testosterone metabolism. *International Journal of Clinical Pharmacology and Therapeutics*, **2021**, 59, 745-752	2	
64	Adrenal insufficiency in HIV/AIDS: a review. *Expert Review of Endocrinology and Metabolism*, **2021**, 1-12	4.1	0
63	Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data. *Therapeutic Advances in Drug Safety*, **2021**, 12, 20420986211041277	3.5	0
62	Characterization of Cytochrome P450 Mechanism-Based Inhibition. 1		2
61	Drug Interactions. 344-359		2
60	Inactivation of Human Cytochrome P450 Enzymes and Drug Drug Interactions. **2010**, 473-495		2
59	Introduction to Drug-Drug Interactions. **2011**, 1-10		5
58	Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion. **2018**, 15-47		1
57	Applications of AmpliChip CYP450. *Molecular Diagnosis and Therapy*, **2005**, 9, 119-27		69
56	Role of Genetic Polymorphisms of Cytochrome P450 2C19 in Pantoprazole Metabolism and Pantoprazole-based Eradication Regimens. *Current Drug Metabolism*, **2020**, 21, 830-837	3.5	2

55	Pharmacokinetic drug interactions in liver disease: An update. *World Journal of Gastroenterology*, **2016**, 22, 1260-78	5.6	43
54	The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis. *Annals of Translational Medicine*, **2014**, 2, 7	3.2	20
53	Human Cytochrome P450 Enzyme Modulation by : A Predictive Safety Evaluation by LC-MS/MS. *Pharmacognosy Magazine*, **2016**, 12, S389-S394	0.8	6
52	Gender Differences in the Pharmacokinetics of Oral Drugs. *Pharmacology & Pharmacy*, **2011**, 02, 31-41	0.3	10
51	Effect of Clarithromycin on the Pharmacokinetics of Ambroxol in Rats. *Journal of Korean Pharmaceutical Sciences*, **2006**, 36, 157-160		2
50	HIV, drugs and the kidney. *Drugs in Context*, **2020**, 9,	5.2	7
49	Therapeutic effect of baicalin on inflammatory bowel disease: A review. *Journal of Ethnopharmacology*, **2022**, 283, 114749	5	2
48	Staying in rhythm: identifying risk factors for Torsade de pointes. *Orthopedics*, **2005**, 28, 1417-20	1.5	1
47	Drug Discovery Trends. **2006**, 1-32		
46	Drug Interactions. **2007**, 97-104		1
45	Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug□Drug Interactions. 1		
44	Automated Drug Screening for ADMET Properties.		
43	Pharmacogenetics and Pharmacogenomics. 1		
42	Bridging Studies in Pharmaceutical Safety Assessment. 1		1
41	Further Reading. 378-407		
40	CHAPTER 13:Cobicistat and Ritonavir as Pharmacoenhancers for Antiviral Drugs. *RSC Drug Discovery Series*, **2013**, 451-481	0.6	
39	Heart-Stopping Treatment. **2015**, 589-592		
38	Antitubulin Agents: Colchicine, Vinca Alkaloids, and Podophyllin. **2017**, 1387-1409		

37	Evaluation of cytochrome P450 3A4-mediated drug-drug interaction potential between P2Y12 inhibitors and statins. *Molecular Medicine Reports*, **2019**, 20, 4713-4722	2.9	2
36	Clinically Relevant Interactions with Anti-Infectives on Intensive Care Units-A Multicenter Delphi Study. *Antibiotics*, **2021**, 10,	4.9	0
35	Premedication of hemin for eradication therapy of in patients with porphyria. *Clinical Case Reports (discontinued)*, **2021**, 9, 944-946	0.7	
34	CHAPTER 13:Toxicology Aspects of Turmeric. *Food Chemistry, Function and Analysis*, **2020**, 293-306	0.6	
33	Molecular modeling and structural analysis of some tetrahydroindazole and cyclopentanepyrazole derivatives as COX-2 inhibitors. *Arabian Journal of Chemistry*, **2021**, 15, 103540	5.9	1
32	A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer. *Therapeutics and Clinical Risk Management*, **2007**, 3, 665-73	2.9	14
31	Long-term and per rectum disposition of Clarithromycin in the desert tortoise (Gopherus agassizii). *Journal of the American Association for Laboratory Animal Science*, **2008**, 47, 41-5	1.3	8
30	Drug interactions: a primer for the gastroenterologist. *Gastroenterology and Hepatology*, **2012**, 8, 376-83	0.7	4
29	Dose-dependent effects of Hedyotis diffusa extract on the pharmacokinetics of tamoxifen, 4-hydroxytamoxifen, and N-desmethyltamoxifen. *Biomedicine and Pharmacotherapy*, **2021**, 145, 112466	7.5	3
28	Cytochrome P450 Enzymes and Drug Metabolism in Humans. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	15
27	Adverse Effects of Anti-Covid-19 Drug Candidates and Alcohol on Cellular Stress Responses of Hepatocytes.. *Hepatology Communications*, **2021**,	6	0
26	Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A.. *Journal of Medicinal Chemistry*, **2022**,	8.3	1
25	Synthesis and in silico evaluation of novel uridyl sulfamoylbenzoate derivatives as potential anticancer agents targeting M1 subunit of human ribonucleotide reductase (hRRM1). *Medicinal Chemistry Research*, 1	2.2	
24	Discovery of DS-3801b, a non-macrolide GPR38 agonist with N-methylanilide structure.. *Bioorganic and Medicinal Chemistry Letters*, **2022**, 128554	2.9	1
23	Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.. *BMC Gastroenterology*, **2022**, 22, 49	3	3
22	Effect of Mild and Moderate Hepatic Impairment (defined by Child Pugh classification and National Cancer Institute-Organ Dysfunction Working Group criteria) on Pexidartinib Pharmacokinetics.. *Journal of Clinical Pharmacology*, **2022**,	2.9	0
21	Cytochrome P450 reaction phenotyping of itraconazole hydroxylation in the dog.. *Journal of Veterinary Pharmacology and Therapeutics*, **2022**,	1.4	
20	Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.. *International Journal of Environmental Research and Public Health*, **2021**, 18,	4.6	2

19	Energy Decomposition Analysis of the Nature of Coordination Bonding at the Heme Iron Center in Cytochrome P450 Inhibition.. *Chemistry - an Asian Journal*, **2022**,	4.5	1
18	Nevirapine Concentrations in HIV-Infected Children treated with Divided Fixed-Dose Combination Antiretroviral Tablets in Malawi and Zambia. *Antiviral Therapy*, **2007**, 12, 253-260	1.6	34
17	Inhibitory effects of Triphala on CYP isoforms in vitro and its pharmacokinetic interactions with phenacetin and midazolam in rats. *Heliyon*, **2022**, 8, e09764	3.6	
16	New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. *Antimicrobial Agents and Chemotherapy*,	5.9	2
15	Identification and Characterization of Genes Related to the Prognosis of Hepatocellular Carcinoma Based on Single-Cell Sequencing. 28,		
14	Probiotics media: significance, challenges, and future perspective - a□mini review. **2022**, 4,		0
13	In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir. **2022**, 365, 110097		1
12	Role of drug-metabolizing enzymes in biotransformation of drugs. **2022**, 73-108		0
11	Mechanism-based inhibition of CYP3A subfamilies by macrolide antibiotics and piperine. **2022**, 15,		0
10	Label-free chemical imaging of cytochrome P450 activity by Raman microscopy. **2022**, 5,		0
9	Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.		0
8	Assessment of potential drug□drug interactions among outpatients in a tertiary care hospital: focusing on the role of P-glycoprotein and CYP3a4 (retrospective observational study). **2022**, e11278		0
7	Molecular Insights into the Heterotropic Allosteric Mechanism in Cytochrome P450 3A4-Mediated Midazolam Metabolism.		0
6	Characterization of Cytochrome P450 Mechanism Based Inhibition. **2022**, 465-526		0
5	What Is Known about Midazolam? A Bibliometric Approach of the Literature. **2023**, 11, 96		0
4	Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety. **2023**, 15, 404		0
3	Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation. **2023**, 24, 6771		0
2	Evaluation of oxidative stress-mediated cytotoxicity and genotoxicity of copper and flubendiamide: amelioration by antioxidants in vivo and in vitro.		0

1	Synthesis and biological evaluation of coumarin derivatives as selective CYP2A6 inhibitors. **2023**, 86, 129206	0